Let's Get Started

Biotech

ConforMIS Inc. (NASDAQ:CFMS) is Attracting Smart Money

Apr 12, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), ConforMIS Inc. (NASDAQ:CFMS) reported that Aeris Capital Archer L.p. has picked up 1,480,349 of common stock as of 2017-04-12.

The acquisition brings the aggregate amount owned by Aeris Capital Archer L.p. to a total of 1,480,349 representing a 3.4% stake in the company.

For those not familiar with the company, ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient’s knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.

A glance at ConforMIS Inc. (NASDAQ:CFMS)’s key stats reveals a current market capitalization of 223.92 Million based on 43.82 Million shares outstanding and a price at last close of $5.14 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-05-17, Law picked up 1,600 at a purchase price of $6.20. This brings their total holding to 24,793 as of the date of the filing.

On the sell side, the most recent transaction saw Steines unload 5,000 shares at a sale price of $5.00. This brings their total holding to 195,745.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on ConforMIS Inc. (NASDAQ:CFMS) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Guess Who Picked Castlight Health Inc. (NYSE:CSLT) Shares

Apr 12, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Castlight Health Inc. (NYSE:CSLT) reported that Venrock Associates Vi, L.p. has picked up 20,783,255 of common stock as of 2017-04-12.

The acquisition brings the aggregate amount owned by Venrock Associates Vi, L.p. to a total of 20,783,255 representing a 22.2% stake in the company.

For those not familiar with the company, Castlight Health, Inc. offers a health benefits platform that engages employees to make healthcare decisions, and enables employers to communicate and measure their benefit programs. The Company operates through cloud-based products segment. Its technology offering aggregates data and applies analytics to make healthcare data transparent. Its products deliver employee engagement and enable employers to integrate benefit programs into a single platform available to employees and their families. Its health benefits platform engages external data and its substantial user base to provide a single, end-to-end solution that engages employees through personalized and relevant communications. Its offering provides employers the opportunity to communicate, measure, and get value out of their benefits and programs on a real-time basis. It offers cross-sell products, such as Castlight Action, Castlight Pharmacy, Castlight Dental, Castlight Elevate, Castlight Protect and Castlight Rewards.

A glance at Castlight Health Inc. (NYSE:CSLT)’s key stats reveals a current market capitalization of 442.79 Million based on 50.02 Million shares outstanding and a price at last close of $4.10 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-11-18, Roberts picked up 121,300 at a purchase price of $3.85. This brings their total holding to 1,256,730 as of the date of the filing.

On the sell side, the most recent transaction saw Nolan unload 270 shares at a sale price of $3.45. This brings their total holding to 33,149.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Castlight Health Inc. (NYSE:CSLT) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Duggan Robert Picked Pulse Biosciences Inc(NASDAQ:PLSE) Shares

Apr 11, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Pulse Biosciences Inc. (NASDAQ:PLSE) reported that Duggan Robert W has picked up 2,578,950 of common stock as of 2017-04-11.

The acquisition brings the aggregate amount owned by Duggan Robert W to a total of 2,578,950 representing a 18.2% stake in the company.

For those not familiar with the company, Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.

A glance at Pulse Biosciences Inc. (NASDAQ:PLSE)’s key stats reveals a current market capitalization of 351.73 Million based on 14.14 Million shares outstanding and a price at last close of $23.18 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-04-10, Duggan picked up 22,764 at a purchase price of $21.40. This brings their total holding to 2,578,950 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Pulse Biosciences Inc. (NASDAQ:PLSE) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Here’s Who Just Picked Up Alliance Healthcare Services Inc. (NASDAQ:AIQ) Shares

Apr 11, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Alliance Healthcare Services Inc. (NASDAQ:AIQ) reported that Fujian Thai Hot Investment Co., Ltd. has picked up 5,537,945 of common stock as of 2017-04-11.

The acquisition brings the aggregate amount owned by Fujian Thai Hot Investment Co., Ltd. to a total of 5,537,945 representing a 51.1% stake in the company.

For those not familiar with the company, Alliance HealthCare Services, Inc. (Alliance) is a provider of outsourced healthcare services to hospitals and providers. The Company operates through three segments: Radiology Division, Oncology Division and Interventional Healthcare Services Division. The radiology segment comprises diagnostic imaging services, including magnetic resonance imaging (MRI), positron emission tomography/computed tomography (PET/CT) and other imaging services. The radiology segment also comprises radiation oncology services. The interventional healthcare services segment provides interventional healthcare through therapeutic minimally invasive pain management procedures medical management, laboratory testing and other services. The Company operates freestanding outpatient radiology, oncology and interventional clinics, and Ambulatory Surgical Centers (ASC) that are not owned by hospitals or providers. It operates over 560 diagnostic imaging and radiation therapy systems.

A glance at Alliance Healthcare Services Inc. (NASDAQ:AIQ)’s key stats reveals a current market capitalization of 136.64 Million based on 10.81 Million shares outstanding and a price at last close of $12.65 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-05-19, Longmore-Grund picked up 2,500 at a purchase price of $7.59. This brings their total holding to 2,500 as of the date of the filing.

On the sell side, the most recent transaction saw Spurlock unload 5,812 shares at a sale price of $29.53. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Alliance Healthcare Services Inc. (NASDAQ:AIQ) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
See who picked Bellicum Pharmaceuticals (NASDAQ:BLCM)

See who picked Bellicum Pharmaceuticals (NASDAQ:BLCM)

Apr 11, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) reported that Baker Bros. Advisors has picked up 5,032,313 of common stock as of 2017-04-11.

The acquisition brings the aggregate amount owned by Baker Bros. Advisors to a total of 5,032,313 representing a 15.2% stake in the company.

For those not familiar with the company, Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-601 and BPX-701. The Company’s CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.

A glance at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM)’s key stats reveals a current market capitalization of 457.66 Million based on 32.16 Million shares outstanding and a price at last close of $12.86 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-03-24, Baker picked up 151,177 at a purchase price of $12.00. This brings their total holding to 4,527,089 as of the date of the filing.

On the sell side, the most recent transaction saw Slawin unload 30,000 shares at a sale price of $12.54. This brings their total holding to 294,982.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Here’s Who Just Picked Up Eleven Biotherapeutics Inc. (NASDAQ:EBIO) Shares

Here’s Who Just Picked Up Eleven Biotherapeutics Inc. (NASDAQ:EBIO) Shares

Apr 7, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Eleven Biotherapeutics Inc. (NASDAQ:EBIO) reported that Flagship Ventures Fund 2007, L.p. has picked up 829,982 of common stock as of 2017-04-07.

The acquisition brings the aggregate amount owned by Flagship Ventures Fund 2007, L.p. to a total of 829,982 representing a 3.4% stake in the company.

For those not familiar with the company, Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

A glance at Eleven Biotherapeutics Inc. (NASDAQ:EBIO)’s key stats reveals a current market capitalization of 47.44 Million based on 24.70 Million shares outstanding and a price at last close of $1.98 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2014-02-11, Flagship picked up 32,912 at a purchase price of $10.00. This brings their total holding to 293,268 as of the date of the filing.

On the sell side, the most recent transaction saw Mccabe unload 1,399 shares at a sale price of $2.10. This brings their total holding to 5,930.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Eleven Biotherapeutics Inc. (NASDAQ:EBIO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Heartland Advisors Inc. is Buying Intricon Corp (NASDAQ:IIN) Shares

Heartland Advisors Inc. is Buying Intricon Corp (NASDAQ:IIN) Shares

Apr 6, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Intricon Corp (NASDAQ:IIN) reported that Heartland Advisors Inc. has picked up 804,877 of common stock as of 2017-04-06.

The acquisition brings the aggregate amount owned by Heartland Advisors Inc. to a total of 804,877 representing a 1.8% stake in the company.

For those not familiar with the company, IntriCon Corporation is engaged in designing, developing, engineering, manufacturing and distributing body-worn devices. The Company operates through body-worn device segment. The Company serves the body-worn device market by designing, developing, engineering and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies, complete assemblies and software solutions, primarily for the value hearing health market, the medical bio-telemetry market and the professional audio communication market. The Company has facilities in Minnesota, California, Singapore, Indonesia, the United Kingdom and Germany, and operates through its subsidiaries. The Company’s product offering includes a hearing aid discount program for health plans. This program is available around the nation to health insurers, including employer-sponsored, individual and Medicare plans. The Company also has various international value hearing aid (VHA) initiatives.

A glance at Intricon Corp (NASDAQ:IIN)’s key stats reveals a current market capitalization of 55.30 Million based on 6.82 Million shares outstanding and a price at last close of $8.30 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2013-08-13, Longval picked up 1,000 at a purchase price of $3.00. This brings their total holding to 16,929 as of the date of the filing.

On the sell side, the most recent transaction saw Geraci unload 2,542 shares at a sale price of $7.58. This brings their total holding to 1,426.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Intricon Corp (NASDAQ:IIN) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Here’s Who Just Picked Up Echo Therapeutics Inc. (NASDAQ:ECTE) Shares

Apr 6, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Echo Therapeutics Inc. (NASDAQ:ECTE) reported that Schoenbart Alan Wayne has picked up 774,500 of common stock as of 2017-04-06.

The acquisition brings the aggregate amount owned by Schoenbart Alan Wayne to a total of 774,500 representing a 5.6% stake in the company.

For those not familiar with the company, Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.

A glance at Echo Therapeutics Inc. (NASDAQ:ECTE)’s key stats reveals a current market capitalization of 1.68 Million based on 12.00 Million shares outstanding and a price at last close of $0.140 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-20-20, Schoenbart picked up 2,500 at a purchase price of $1.44. This brings their total holding to 2,500 as of the date of the filing.

On the sell side, the most recent transaction saw Young unload 10,000 shares at a sale price of $2.38. This brings their total holding to 160,874.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Echo Therapeutics Inc. (NASDAQ:ECTE) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Guess who is Buying Vycor Medical Inc. (OTCMKTS:VYCO) Shares

Apr 6, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Vycor Medical Inc. (OTCMKTS:VYCO) reported that Fountainhead Capital Management Ltd has picked up 10,579,097 of common stock as of 2017-04-06.

The acquisition brings the aggregate amount owned by Fountainhead Capital Management Ltd to a total of 10,579,097 representing a 50.10% stake in the company.

For those not familiar with the company, Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company operates through two segments: Vycor Medical, which focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals, and NovaVision, which focuses on neuro-stimulation therapies and diagnostic devices for the treatment and screening of vision field loss resulting from neurological damage. The Company designs, develops and markets neurological medical devices and therapies. The Company operates in the United States and Europe. Vycor Medical’s product Vycor Medical’s ViewSite Brain Access System (VBAS) is a next generation retraction and access system. VBAS is a disposable product that can be used with microscopic, endoscopic and neuro-navigation systems. NovaVision has a family of therapies that both restore and compensate for lost vision. NovaVision’s products include VRT and Neuro-Eye Therapy (NeET), NeuroEyeCoach and Vision Diagnostic (VIDIT)..

A glance at Vycor Medical Inc. (OTCMKTS:VYCO)’s key stats reveals a current market capitalization of 3.48 Million based on 17.42 Million shares outstanding and a price at last close of $0.200 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2014-12-31, Fountainhead picked up 8,380 at a purchase price of $1.79. This brings their total holding to 4,366,844 as of the date of the filing.

On the sell side, the most recent transaction saw Bronsther unload 6,241 shares at a sale price of $2.75. This brings their total holding to 18,216.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Vycor Medical Inc. (OTCMKTS:VYCO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more